However, the vulnerability of RGCs to pathogenic tau accumulation in AD patients, particularly during the earliest stages of functional impairment (MCI due to AD), and its potential relationship with disease status, has not yet been explored. The gene discussed is MAPT; the disease is Alzheimer disease.